Sanofi Sarclisa combo gains approval as first-line multiple myeloma treatment

RomanBabakin/iStock Editorial via Getty Images The U.S. FDA has granted an additional indication for Sanofi's Sarclisa (isatuximab) as a first-line therapy for multiple myeloma in combination with Johnson & Johnson's ( JNJ )/Takeda's ( TAK ) Velcade (bortezomib), Bristol Myers Squibb's ( BMY ) Revlimid (lenalidomide), and dexamethasone.

Phase 3 data.